Skip to main content
SpringerLink
Log in

Drug Safety Evaluation in China

  • Pediatric Allergy and Immunology (W Dolen, Section Editor)
  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This review aimed to introduce the regulations management and current situations of drug safety evaluation in China.

Recent Findings

The nationwide implementation of good laboratory practice and good clinical practice guarantees the quality of pre-marketing drug safety evaluation. In recent years, post-marketing drug safety monitoring is changing from passive mode to the combination of active and passive monitoring. A national adverse drug reaction monitoring sentinel alliance has been created to actively identify, report, and evaluate adverse reactions, with more than 1.4 million cases reported in 2017. But the quality of the reports is not optimal, with few reports from drug manufacturers, low rate of severe reports, and trend of lag reporting.

Summary

Drug safety evaluation in China is transitioning from passive monitoring to a combination mode. Drug pharmacovigilance is a powerful tool for active monitoring, but participation by drug manufacturers would be essential to an effective drug safety evaluation system.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Xu H, Lu Z. Current situation and countermeasure of drug safety supervision and management in China. Chin Med Mod Dist Educ Chin. 2016;14(18):29–31.

    Google Scholar 

  2. Lu G. Comprehensive evaluation of drug non-clinical safety evaluation. Beijing Med J. 2015;37(3):208–9.

    Google Scholar 

  3. Decision of the council concerning the mutual acceptance of data in the assessment of chemicals. In: OECD Legal Instruments. Organization for Economic Cooperation and Development. 1981. https://legalinstruments.oecd.org/en/instruments/OECD-LEGAL-0194. Accessed 14 June 2019

  4. Drug Administration Law of People’s Republic of China. National People’s Congress of the People’s Republic of China. 2015. http://www.npc.gov.cn/npc/lfzt/rlyw/2018-10/19/content_2062728.htm?from=singlemessage. Accessed 14 June 2019.

  5. Li L, Lv L, Chen J, Zhang Q, Pang J. China’s good laboratory practice and mutual acceptance of safety data. Chin Pharm Aff. 2008;22(7):531–3.

    Google Scholar 

  6. Xiong Z. Introduction of GLP in China. Her Med. 2005;24(8):751–2.

    Google Scholar 

  7. Li B. Overview of good laboratory practice (GLP). China Pharm. 2007;10(1):36–9.

    Google Scholar 

  8. Notice on promoting the implementation of good laboratory practice (GLP). China Food and Drug Administration. 2006. http://samr.cfda.gov.cn/WS01/CL0844/10619.html. Accessed 14 June 2019.

  9. Interpretation of good laboratory practice (GLP). China Food and Drug Administration. 2017. http://samr.cfda.gov.cn/WS01/CL1790/175545.html. Accessed 14 June 2019.

  10. Wang X, Ma J. Research advances of new techniques and methods for drug safety evaluation. Chin J Pharm. 2017;48(3):341–50.

    Google Scholar 

  11. Yang Y, Hu Y, Zhou J, Cao C, Wang Z. The current situation, problems and the thoughts concerning the construction of the GLP quality systems in China. Cap Med. 2013;24:17–9.

    Google Scholar 

  12. Zhang J. Accelerating GLP construction and MAD process in China. Int Econ Coop. 2017;12:16–9.

    Google Scholar 

  13. Good clinical practice (Administration Order No. 13). China Food and Drug Administration. 1999. http://samr.cfda.gov.cn/WS01/CL0053/24493.html. Accessed 14 June 2019.

  14. Good clinical practice (Administration Order No. 3). China Food and Drug Administration. 2003. http://samr.cfda.gov.cn/WS01/CL0053/24473.html. Accessed 14 June 2019.

  15. Xiang Y, Huang Z, Liu C, Yang G. Construction of quality management system with Chinese characteristic for drug clinical trial institution. Chin J Clin Pharmacol. 2017;33(11):1039–41.

    Google Scholar 

  16. Liu S, Wei J. Discussion on standardization of adverse event management in drug clinical trials. Heilongjiang Med J. 2016;40(11):1051–2.

    Google Scholar 

  17. Zheng W, Liu Z, Lei X, Tian R, Zhen R, Li N, et al. Establish research model of post-marketing clinical safety evaluation for Chinese patent medicine. China J Chin Mater Med. 2015;40(18):3693–6.

    Google Scholar 

  18. Li Y. Clinical safety evaluation of new drugs. Chin J Pharmacoepidemiol. 2004;13(6):287–90.

    Google Scholar 

  19. Li S, Yan M, Wu Y, Guo X. Related requirement of evaluation of clinical drug safety and good clinical practice. Chin J Pharmacoepidemiol. 2003;12(1):1–6.

    Google Scholar 

  20. •• Shu T, Chen W, Hou Y, Chen G, Zhou K, Zhang Y. Research and application of the sentinel hospital pharmacovigilance system based on HIS. China Pharm. 2017;28(25):3468–71. COMMENT: This article introduced in detail the working process and achievement of adverse drug reaction monitoring by sentinel hospitals through Chinese hospital pharmacovigilance system.

    Google Scholar 

  21. Administrative measures on reporting and monitoring of adverse drug reaction. Ministry of Health. 2004. http://samr.cfda.gov.cn/WS01/CL0053/24477.html. Accessed 14 June 2019.

  22. Notice on the issuance of national 12th five-year plan for drug safety. China State Council. 2012. http://www.gov.cn/zhengce/content/2012-02/13/content_6119.htm. Accessed 14 June 2019.

  23. Yang L, Tian L, Luo G. Comparative research and enlightenment on active post-marketing drug safety surveillance systems from the global perspective. Sci Technol Manag Res. 2017;7:182–90.

    Google Scholar 

  24. Wang L. Opportunities and challenges in using medical big data to monitor and evaluate drug safety. Chin J Pharmacov. 2015;12(11):660–4.

    Google Scholar 

  25. Shen L, Liu W, Guo X, Peng L, Kong F, Li X. Ideas on trend of ADR monitoring model in China. Chin J Pharmacov. 2017;14(5):295–7.

    Google Scholar 

  26. Zhou W, Liu A, Du G. The comparative study on the monitoring system of adverse drug reaction between China and UK. Chin J Drug Eval. 2015;32(6):376–80.

    Google Scholar 

  27. Notice on the issuance of national 13th five-year plan for food safety and drug safety. China State Council. 2017. http://www.gov.cn/zhengce/content/2017-02/21/content_5169755.htm. Accessed 14 June 2019.

  28. Administrative measures on reporting and monitoring of adverse drug reaction. Ministry of Health. 2011. http://www.gov.cn/flfg/2011-05/24/content_1870110.htm. Accessed 14 June 2019.

  29. Tian K, Gao J, Miu J, Wan K, Yu C, Zhou J, et al. Analysis of adverse drug reaction monitoring and inspection system for drug manufacturers in our province. Chin J Pharmacov. 2014;11(5):285–90.

    Google Scholar 

  30. •• Sun J. Review and inspiration of adverse drug reaction monitoring milestones in 2017. Pharm Clin Res. 2018;26(1):3–6. COMMENT: This article reviewed recent highlights and future trend of adverse drug reaction monitoring in China.

    Google Scholar 

  31. Wang L, Zhou J, Zhang X, Lin X. Practice and investigation on data normalization of adverse drug reaction reporting. Chin J Pharmacov. 2014;11(7):407–12.

    CAS  Google Scholar 

  32. National annual report of adverse drug reaction monitoring (2017). China Food and Drug Administration. 2018. http://www.cdr-adr.org.cn/xwdt/201804/t20180419_20011.html. Accessed 14 June 2019.

  33. Jin F, Qu Y, Fan R, Li X. Research of the present situation of construction and countermeasures in nationwide provincial adverse drug reaction monitoring organizations. Chin J Pharmacov. 2015;12(4):224–8.

    Google Scholar 

  34. Shi J. Drug safety and adverse drug reaction monitoring. Strait Pharm J. 2007;19(1):90–2.

    Google Scholar 

  35. National annual report of adverse drug reaction monitoring (2012). China Food and Drug Administration. 2013. https://baike.baidu.com/item/2012%E5%B9%B4%E5%9B%BD%E5%AE%B6%E8%8D%AF%E5%93%81%E4%B8%8D%E8%89%AF%E5%8F%8D%E5%BA%94%E7%9B%91%E6%B5%8B%E5%B9%B4%E5%BA%A6%E6%8A%A5%E5%91%8A/17023321?fr=aladdin. Accessed 14 June 2019.

  36. National annual report of adverse drug reaction monitoring (2013). China Food and Drug Administration. 2014. http://samr.cfda.gov.cn/WS01/CL1989/99794.html. Accessed 14 June 2019.

  37. National annual report of adverse drug reaction monitoring (2014). China Food and Drug Administration. 2015. http://samr.cfda.gov.cn/WS01/CL1989/124407.html. Accessed 14 June 2019.

  38. National annual report of adverse drug reaction monitoring (2015). China Food and Drug Administration. 2016. http://samr.cfda.gov.cn/WS01/CL0844/158940.html. Accessed 14 June 2019.

  39. National annual report of adverse drug reaction monitoring (2016). China Food and Drug Administration. 2017. http://samr.cfda.gov.cn/WS01/CL0844/172167.html. Accessed 14 June 2019.

  40. Du H, Liu J. Current situation of adverse drug reaction monitoring and prospect in PAP. J Log Univ CAPF. 2015;24(8):654–6.

    Google Scholar 

  41. Wang L. Study on adverse drug reaction monitoring based on hospital information system. Chin J Pharmacov. 2015;12(4):229–31.

    Google Scholar 

  42. Sun P, Liu X, Liang Y. Work model and experience investigation of the development of pharmacovigilance in our hospital. China Pharm. 2011;22(34):3169–71.

    Google Scholar 

  43. Yu C, Xu Y, Li X, Wang L, Zhou J, Wan K, et al. Demand investigation of interconnection between hospital information system and national adverse drug reaction monitoring system in China. Chin J Pharmacov. 2016;13(3):154–8.

    Google Scholar 

  44. Yuan X, Gao J, Zhou J, Zhong C, Ren J. The status and prospective of PSUR in China. Chin J Pharmacov. 2014;11(6):333–9.

    Google Scholar 

  45. Peng L, Fan Y, Li X. Discussion on how drug manufacturers fulfill the first person responsibilities of post-marketing drug safety. Chin J Pharmacov. 2016;13(3):159–61.

    Google Scholar 

  46. Wang Y. Study on the adverse drug reaction monitoring mode Chinese trend. China Health Stand Manag. 2017;8(24):87–9.

    Google Scholar 

  47. Wang X, Lu C, Zhao Y, Wu S, Wang L, Tian Y, et al. Investigation and reflection on the way and content of public reporting of adverse drug reactions in China. Chin J Pharmacov. 2017;14(7):413–8.

    Google Scholar 

  48. Li D, Zhang J, He W. The problems in the adverse drug reaction reports of Haidian District in Beijing: the reports were incomprehensive, delayed and nonstandardized. Cap Food Drug. 2016;23(15):39.

    Google Scholar 

  49. Ban B, Wei J, Li E, Zhou L, Sun R. Status analysis of the adverse drug reaction monitoring work basing on the quantity and quality of ADR reports. Chin J Pharmacov. 2016;13(6):344–6.

    Google Scholar 

  50. Yu Z, Lv A, Wu P, Peng J, Shan Z, Ju D, et al. Considerations on traditional Chinese medicine safety studies. Chin J Basic Med Trad Chin Med. 2003;9(5):66–8.

    CAS  Google Scholar 

  51. Li S, Li M, Wei Y, Li C. Review on research of safety evaluation for traditional Chinese medicine. Mod Chin Med. 2014;16(2):172–6.

    Google Scholar 

  52. Sun Z, Zhou L, Han L. Key principles of nonclinical safety evaluation for pediatric drugs and characteristics of traditional Chinese materia medica evaluation. Chin J Pharmacol Toxicol. 2016;30(1):13–20.

    Google Scholar 

  53. Cen X, Han L. Consideration on non-clinical safety evaluation of traditional Chinese medicine. Chin J Pharmacol Toxicol. 2016;30(12):1343–58.

    Google Scholar 

  54. Xu X, Jiang Z, Huang X, Zhang L. Determination of aristolochic acid I in rats by HPLC and its toxicokinetics. Chin J Clin Pharmacol Ther. 2008;13(2):144–8.

    Google Scholar 

  55. Wang D, Qiu L, Wu X, Wei H, Xu F. Evaluation of kudzu root extract-induced hepatotoxicity. J Ethnopharmacol. 2015;176:321–6.

    Article  CAS  Google Scholar 

  56. Cai Y, Gao Y, Tan G, Wu S, Dong X, Lou Z, et al. Myocardial lipidomics profiling delineate the toxicity of traditional Chinese medicine Aconiti Lateralis radix praeparata. J Ethnopharmacol. 2013;147(2):349–56.

    Article  CAS  Google Scholar 

  57. Su T, Tan Y, Tsui MS, Yi H, Fu XQ, Li T, et al. Metabolomics reveals the mechanisms for the cardiotoxicity of Pinelliae Rhizoma and the toxicity-reducing effect of processing. Sci Rep. 2016;6:34692.

  58. Pan H, Wu W, Shen H, Guan L. Genetic diversity analysis of soluble protein profile of Sichuan Pinellia ternata. Lishizhen Med Mater Med Res. 2011;22(11):2781–3.

    CAS  Google Scholar 

  59. Liang Q, Ni C, Yan X, Xie M, Zhang Y, Zhang Q, et al. Comparative study on metabonomics and on liver and kidney toxicity of Aristolochia fangchi and Stephania tetrandra. China J Chin Mater Med. 2010;35(21):2882–8.

    Google Scholar 

  60. General principles of clinical research on new traditional chinese medicine treatments. China Food and Drug Administration. 2015. http://samr.cfda.gov.cn/WS01/CL1616/134582.html. Accessed 14 June 2019.

  61. Liu B. Interpretation and drafting instructions of general guidelines of clinical trials on new drugs of traditional Chinese medicine (TCM). World Sci Techn/Mod Trad Chin Med Mat Med. 2016;18(12):2075–81.

  62. Bi F, Zhang L. Discussion on the safety of traditional Chinese medicine injection. Chin J Pharmacov. 2012;9(2):89–92.

    Google Scholar 

Download references

Acknowledgments

We thank DONG Jiangping (chief pharmacist, Center for Food and Drug Inspection of National Medical Products Administration), DONG Duo (chief pharmacist, National Center for Adverse Drug Reaction Monitoring, China), and HUO Yan (research fellow, National Institutes for Food and Drug Control) for their great help in revising this manuscript.

Author information

Authors and Affiliations

  1. Department of Allergy, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment on Allergic Diseases, National Clinical Research Center for Immunologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China

    Lisha Li & Jia Yin

Authors
  1. Lisha Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jia Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jia Yin.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Pediatric Allergy and Immunology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, L., Yin, J. Drug Safety Evaluation in China. Curr Allergy Asthma Rep 19, 39 (2019). https://doi.org/10.1007/s11882-019-0872-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11882-019-0872-4

Keywords

Search

Navigation